Yep, and the longer the CEO doesn't update shareholders the more concerned we become. No issues with the science & progress but a strategic update from the guy who prides himself on "honing a strategic vision"
may alleviate some concerns. Shareholders are dismayed at the lack of information flow about company's operations, resulting in the SP extending a long term downtrend. On face value, the company has a complete disregard for the current SP.
All leverage has basically been lost if discussing with potential partners, whether licensing or acquisition. And whatever happened to those deep-pocketed investors? Deals are constantly being made in the biotech space for companies still in the pre-clinical stage, yet here we are. Joel's silence is deafening.
Been waiting for the next quarterly to at least give me something. Anything.